Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8804060 | Seminars in Arthroplasty | 2017 | 20 Pages |
Abstract
The goals of treatment for ONFH are to preserve function, reduce pain, and delay the need for THA. Our study has demonstrates that CD-BMAC may be a worthwhile treatment modality in patients with stage I or II ONFH. However, future randomized control trials comparatively evaluating the effectiveness of CD-BMAC to a control are necessary to better understand the clinical impact associated with BMAC therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Orthopedics, Sports Medicine and Rehabilitation
Authors
Thomas A. MD, Afshin A. MD, Kevin K. MA, Ameer BA, Tony MD, Michelle NP, Richard MD,